| Literature DB >> 16251411 |
William E Lawson1, Vasiliy V Polosukhin, Georgios T Stathopoulos, Ornella Zoia, Wei Han, Kirk B Lane, Bo Li, Edwin F Donnelly, George E Holburn, Kenneth G Lewis, Robert D Collins, William M Hull, Stephan W Glasser, Jeffrey A Whitsett, Timothy S Blackwell.
Abstract
Recent reports have linked mutations in the surfactant protein C gene (SFTPC) to familial forms of pulmonary fibrosis, but it is uncertain whether deficiency of mature SP-C contributes to disease pathogenesis. In this study, we evaluated bleomycin-induced lung fibrosis in mice with genetic deletion of SFTPC. Compared with wild-type (SFTPC+/+) controls, mice lacking surfactant protein C (SFTPC-/-) had greater lung neutrophil influx at 1 week after intratracheal bleomycin, greater weight loss during the first 2 weeks, and increased mortality. At 3 and 6 weeks after bleomycin, lungs from SFTPC-/- mice had increased fibroblast numbers, augmented collagen accumulation, and greater parenchymal distortion. Furthermore, resolution of fibrosis was delayed. Although remodeling was near complete in SFTPC+/+ mice by 6 weeks, SFTPC-/- mice did not return to baseline until 9 weeks after bleomycin. By terminal dUTP nick-end labeling staining, widespread cell injury was observed in SFTPC-/- and SFTPC+/+ mice 1 week after bleomycin; however, ongoing apoptosis of epithelial and interstitial cells occurred in lungs of SFTPC-/- mice, but not SFTPC+/+ mice, 6 weeks after bleomycin. Thus, SP-C functions to limit lung inflammation, inhibit collagen accumulation, and restore normal lung structure after bleomycin.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16251411 PMCID: PMC1603790 DOI: 10.1016/S0002-9440(10)61214-X
Source DB: PubMed Journal: Am J Pathol ISSN: 0002-9440 Impact factor: 4.307